ROARABLE
FREE $100K
Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / INNV / options
USPH (70) OMDA (53) PNTG (64) TDOC (55) ⌘ Pro Terminal β†’

InnovAge Holding Corp. (INNV) Options Positioning, Max Pain & Unusual Sweeps

$8.92 -2.94% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.86

InnovAge Holding Corp. (INNV) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ β€’ SELL / AVOID Cap $1.25B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INNV Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is INNV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, InnovAge Holding Corp. (NASDAQ: INNV) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $8.92 (-2.94% 1D, market cap $1.25B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, INNV ranks #243 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does INNV compare to USPH and OMDA in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Nursing Services), INNV carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of 18.0%, and ROIC of -10.2%. By comparison, USPH (U.S. Physical Therapy Inc.) holds a B- grade (70/100 RQD, P/E 32.6x, ROIC 11.5%, cap $1.28B) and OMDA (Omada Health Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC -15.7%, cap $1.15B). Among the 5-stock peer group, USPH leads on earnings multiple (32.6x) while USPH leads on capital efficiency (11.5% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INNV?
β–Ό

Per INNV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001834376), InnovAge Holding Corp. generated $853.7M in revenue (+11.8% YoY), -$30.3M in net income, and $26.6M in free cash flow against $527.5M in total assets and $56.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $8.86 (-0.72%)🧬 Disciplined Float (+0.16% YoY Shares)βš™οΈ Cash Engine: 12/20 (C-) β€’ 3.1% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY β€’ 50.1% hit rate β€” wait for RQD β‰₯ 70 breakout).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D+
025507510052
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D Β· Rk C
Cash (12)Whales (8)SEC (12)Macro (13)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-2.7% Base Target
$13 Bull$9 Base$7 Bear
πŸ“¬ FREE INNV RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for INNV)Realized 20D OHLCV Swing Band: Β±7%
Deterministic 5-Pillar Attribution (52/100 Composite)
πŸ” WHY INNV SCORES 52/100 (D+) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Macro Regime Fit+13/20 pts (25% of score)

FRED Regime Γ— Technicals: 57% of 52W Range β€’ RSI-14 at 45.9 (NEUTRAL RANGE)

β–² #2 Bullish Driver: Cash Engine Quality+12/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 3.1% FCF Margin ($26.6M FCF) & 18% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution7/20 pts (-13 pt drag)

Disciplined Float (+0.16% YoY Shares) & executive Form 4 sales trim 13 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
60
Grade C$9.02+1.4% Next Q
Q2 (-2Q)
57
Grade C$9.15-0.3% Next Q
Q3 (-1Q)
55
Grade C$9.12-2.2% Next Q
Current
52
Grade D+$8.92-1.1% Hist 90D Ξ±
Trajectory: C (60) β†’ D+ (52)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a INNV Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While INNV currently carries a cautious 52/100 (D+) rating due to Insider Conviction & Share Dilution (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.77) and Max Pain ($9.37) forces dealer call-delta covering toward $13.27.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INNVβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œINNV Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
YES 52%NO 48%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±7%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (INNV)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for INNV.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INNV)

  • βœ“Walkthrough of INNV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
INNV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +9.18%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $9.24H $9.24L $8.92C $8.92VOL 593.1K
RES: $11.78SUP: $8.86SMA50: $9.77SMA200: $9.10
$13.11$11.16$9.22$7.27$5.33RES $11.78SUP $8.86$8.922026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INNV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ INNV Butterfly Map β†’ + Track INNV β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +11.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on INNV today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for INNV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INNV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INNV)

Health Care Rank #243 of 1015 βš”οΈ USPH vs INNV Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (INNV vs. USPH, OMDA, PNTG, TDOC)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, InnovAge Holding Corp. (INNV) ranks #243 by composite RQD confidence (52/100, grade D+) and #326 by equity capitalization ($1.25B). Within this direct 5-issuer industry benchmark cohort, USPH leads on earnings valuation at 32.6x trailing P/E, while USPH leads on capital efficiency and profitability with 11.5% ROIC and 19.2% gross margin. USPH currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with INNV at 52/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
INNV ACTIVE
InnovAge Holding Corp.
D+ 52/100 β€” 18.0% -10.2% -2.94% $1.25B Benchmark Subject
USPH
U.S. Physical Therapy Inc.
B- 70/100 32.6x 19.2% 11.5% -1.08% $1.28B /usph-vs-innv β†’
OMDA
Omada Health Inc.
D+ 53/100 β€” 65.7% -15.7% -4.70% $1.15B /omda-vs-innv β†’
PNTG
The Pennant Group Inc.
C 64/100 50.2x β€” 11.0% -2.78% $1.46B /pntg-vs-innv β†’
TDOC
Teladoc Health Inc.
D+ 55/100 β€” β€” -17.0% +1.41% $1.55B /tdoc-vs-innv β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-06-30 β€’ CIK 0001834376 β†—

In its most recent audited fiscal period (FY2025, filed 2025-06-30), InnovAge Holding Corp. (INNV) reported GAAP revenue of $853.7M (+11.8% vs. FY2024 revenue of $763.9M , and +24.1% cumulative change since FY2023) , GAAP net income of -$30.3M, operating cash flow of $32.9M, and free cash flow of $26.6M (+159.4% YoY). On the balance sheet, INNV closed FY2025 with $527.5M in total assets against $56.0M in total debt (Altman Z-Score: 4.47, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $853.7M -$30.3M $32.9M $26.6M $527.5M $56.0M
FY2024 (FY) 2024-06-30 $763.9M -$21.3M -$36.9M -$44.8M $524.8M $59.8M
FY2023 (FY) 2023-06-30 $688.1M -$40.7M $20.2M $20.2M β€” β€”

3. INNV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INNV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, InnovAge Holding Corp. (NASDAQ: INNV) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $8.92 (-2.94% 1D, market cap $1.25B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, INNV ranks #243 in composite RQD confidence.

How does INNV compare to USPH and OMDA in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), INNV carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of 18.0%, and ROIC of -10.2%. By comparison, USPH (U.S. Physical Therapy Inc.) holds a B- grade (70/100 RQD, P/E 32.6x, ROIC 11.5%, cap $1.28B) and OMDA (Omada Health Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC -15.7%, cap $1.15B). Among the 5-stock peer group, USPH leads on earnings multiple (32.6x) while USPH leads on capital efficiency (11.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INNV?

Per INNV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001834376), InnovAge Holding Corp. generated $853.7M in revenue (+11.8% YoY), -$30.3M in net income, and $26.6M in free cash flow against $527.5M in total assets and $56.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INNV trading relative to its 50-day, 200-day, and 52-week technical levels?

INNV last traded at $8.92 (-2.94% on volume of 535,212 shares), positioning the stock -8.70% below its 50-day simple moving average ($9.77) and -1.98% below its 200-day simple moving average ($9.10). Across its 52-week range of $3.93 to $12.64, INNV sits at the 57.3% percentile with a 14-day RSI of 45.9 (NEUTRAL RANGE) and an implied next-earnings move of Β±7.0% ($8.30 to $9.54).

Direct Sub-Reports: INNV RQD Cockpit INNV 12M Forecast INNV Earnings & Move INNV Dividends & DRIP INNV Insiders & 13F INNV Whale Options INNV Profit Sankey INNV News & Why
ROARABLE RATING BRIEF β€’ RQD 52/100 (D+) βœ“ SEC XBRL & RQD VERIFIED

INNV β€” InnovAge Holding Corp.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

InnovAge Holding Corp. (INNV) earns a live Roarable RQD composite score of 52/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $8.92 (-2.94% 1D, market capitalization $1.25B).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of -10.2%, gross margin of 18.0%, operating margin of -3.5%, and free cash flow yield of 2.11%.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (13/20) + Forensic Balance Sheet (12/20): Incorporates a 1.00x equity beta, Altman Z-Score of 4.47, Piotroski F-Score of 6/9, and Debt/Equity of 0.22x.

2. Business Model, Unit Margins & SEC Financial Trajectory

InnovAge Holding Corp. (INNV) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Nursing Services industry. It carries a market capitalization of $1.3B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), InnovAge Holding Corp. (INNV) reported $853.7M in annual revenue (up from $763.9M in FY2024, +11.8% YoY) and -$30.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($688.1M revenue, -$40.7M net income) through FY2025, INNV scaled operating cash flow to $32.9M and free cash flow to $26.6M, backed by $527.5M in total assets against $56.0M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D+ β€’ RQD 52/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 2.11% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $3.93 – $12.64 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -3.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Nursing Services (Health Care), INNV carries a macro regime beta of 1.00 and gross margin of 18.0%.

  • Key Question #1: Can INNV sustain or expand its -3.5% operating margin and -10.2% ROIC against Medical/Nursing Services peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $853.7M and free cash flow of $26.6M, how will capital allocation balance growth reinvestment against $56.0M in total debt?
  • Key Question #3: How sensitive is INNV's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

INNV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for InnovAge Holding Corp. (INNV) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to INNV Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INNV Bull vs. Bear Conversation Board β€” What's Your Call at $8.92?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INNV 🐻 33% BEARISH CONVICTION
1. Pick Your Side on INNV:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER β€’ Cross-Asset Macro Desk πŸ‚ BULLISH 🎯 Target: $12.04 (+31.0%)
πŸ“Œ Pinned Debate

The forensic balance sheet scores 12/20 with an Altman Z of 4.47 and Debt/Equity of 0.22, and FY 2025 FCF turned positive at $26.6M.

Don't sleep on INNV's setup in Health Care. The forensic balance sheet scores 12/20 with an Altman Z of 4.47 and Debt/Equity of 0.22, and FY 2025 FCF turned positive at $26.6M.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (52/100) backs up the fundamental quality.

RetailWhale_TX πŸ‚ BULL

Both sides have a point here β€” INNV's 12/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER β€’ Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $7.81 (-15.0%)
Spot @ $9.19

ROIC is -10.2% and net margin is -3.6%, with the RQD rating at 52/100 and insider sales of 1,500,000 shares reported.

Fading this rally in INNV at $9.19. ROIC is -10.2% and net margin is -3.6%, with the RQD rating at 52/100 and insider sales of 1,500,000 shares reported.. With a beta of 1.0 and the stock sitting at $9.19 (52-wk range $3.93–$12.64), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%